Superiority:
This active molecular is an sodium-proton exchanger NHE3 inhibitor under the development of Ardelyx. This antiporter protein plays a really important role in sodium handling in the gastrointestinal tract and kidney and it regulates the levels of sodium absorbed and secreted by the body. Therefore, tenapanor can be useful in the treatment of chronic kidney disease and hypertension because both of them are exacerbated by excess sodium in the diet. In Oct 2016, Phase-III clinical trials in Hyperphosphataemia (in patients with end-stage renal disease) in USA was on going.
Tenapanor, also known as AZD-1722 and RDX 5791, is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3, which plays a prominent role in sodium handling in the gastrointestinal tract and kidney. Tenapanor possesses an excellent preclinical safety profile and, as of now, there are no serious concerns about its side effects.
Details:
Tenapanor is an inhibitor of the sodium-proton exchanger NHE3. This antiporter protein is found in the kidney and intestines, and normally acts to regulate the levels of sodium absorbed and secreted by the body. When administered orally, tenapanor selectively inhibits sodium uptake in the intestines, limiting the amount absorbed from food, and thereby reduces levels of sodium in the body. This may make it useful in the treatment of chronic kidney disease and hypertension, both of which are exacerbated by excess sodium in the diet.